EDITGENE Launches Prime Editing 7 : A Leap in Gene-Targeted Mutation Technology

Prime Editing (PE) is a cutting-edge gene-editing technology built up on the CRISPR/Cas system. It enables precise genomic modifications, including insertions, deletions, and base substitutions, at targeted sites. By integrating Cas proteins, reverse transcriptase, and tailored guide RNAs (prime editing guide RNAs or pegRNAs), PE overcomes the limitations of traditional mutation methods, delivering exceptional precision and versatility.

EDITGENE has taken this groundbreaking technology to new heights with the launch of Prime Editing 7 (PE7). Designed to excel in both basic research and advanced applications, PE7 sets a new standard in gene editing. Offering enhanced editing capabilities, increased efficiency, and expanded versatility, PE7 empowers researchers to achieve unparalleled precision in their gene-editing endeavors.

PE 7: key Highlights

1、20% Increase in PE Success Rate

With optimized interactions between editing proteins and RNA, Prime Editing 7 (PE7) achieves a 20% improvement in point mutation success rates over PE5. This enhancement ensures greater precision and reliability, reducing costs and enabling researchers to focus on transformative discoveries.

2、4.7x Improved Efficiency at Challenging Sites

PE7 significantly boosts editing performance, reaching up to 86% efficiency at easily editable sites. More notably, it excels at challenging targets, improving efficiency by 1.76x to 4.71x compared to PE5. This breakthrough makes previously difficult edits attainable, unlocking new research potential.

Editing Efficiencies of PE 7 VS PE 5 Across Targeting Sites

Sites where editing failed via PE5, but were successfully edited via PE7

Note: 1 grade<10%, 2 grade20%-30%, 3 grade30%-40%,4 grade50%-60%,5 grade 70%-100%

Improvement in editing efficiency of PE7 compared to PE5

Note: 1 grade<10%, 2 grade20%-30%, 3 grade30%-40%,4 grade50%-60%,5 grade 70%-100%

Why Choose EDITGENE's PE7? Its unmatched performance will transform your research progress.

EDITGENE isn't just upgrading technology—it's transforming gene editing. Whether you're studying gene functions, developing new drugs, or advancing precision medicine, PE7 is the ultimate tool for your research. Imagine the time-consuming, complex gene editing tasks of the past, now made easy with PE7. Each attempt at gene editing becomes a crucial step toward groundbreaking discoveries.

Experience the limitless possibilities of gene editing with EDITGENE's Prime Editing 7. Take control of your next research breakthrough!

EDITGENE is an innovative company founded by PhD scholars with international experience, specializing in the research, development, and commercialization of CRISPR/Cas gene editing technology. Leveraging CRISPR/Cas technology, EDITGENE has developed foundational research platforms, including CRISPR-EDITx™ platform, the Bingo™ leading-edge point mutation platform and the FASST nucleic acid diagnostic platform.EDITGENE has provided comprehensive CRO services to research institutes and pharmaceutical companies worldwide, covering applications such as gene knockout、gene overexpression、point mutation and CRISPR library screening，Additionally, EDITGENE offers CRISPR detection enzymes (such as cas12 and cas13) and custom development services.In the coming future, EDITGENE plans to build the largest and most comprehensive gene editing service platform, providing a full range of gene editing-related services. With the mission of facilitating the widespread application of CRISPR/Cas technology, EDITGENE is committed to advancing the gene editing revolution and driving progress in the science field.